公司为专注于口腔修复材料与数字化设备的专业服务商，分别于2023 年及 2024 年通过参股及收购的方式布局氧化锆粉体及种植牙业务。 目前，公司主要产品包括以氧化锆瓷块、玻璃陶瓷等为主的口腔修复 材料及以椅旁数字化设备为主的口腔数字化设备。其中口腔修复材料 为公司主要收入板块，氧化锆瓷块是核心收入来源。2025 年前三季 度，公司实现营业收入 7.47 亿元，同比增长 16.44%；归母净利润 1.42 亿元，同比增长 27.2%。公司资产负债率较低，期间费用率受韩国沃 兰营销需求影响略有提升，盈利能力持续保持稳定。 2026 年 03 月 19 日 爱迪特(301580.SZ) 齿科材料领先企业，国产替代正当时 口腔修复材料及数字化设备领军企业，盈利能力稳健： 海外氧化钇价格提升，瓷块产业或加速国产替代： 2025 年以来新一轮关税博弈叠加 2026 年 1 月对日稀土管控升级，国 内稀土管控政策持续收紧，推动海外氧化钇价格大幅上涨。截至 2026 年 3 月海外氧化钇价格涨幅超 45 倍，海内外价差高达 36 倍。氧化钇 作为牙用钇稳定氧化锆（Y-TZP）的核心稳定剂，是牙科全瓷修复体 的核心原料。当前全 ...

证券代码：301580 证券简称：爱迪特 爱迪特（秦皇岛）科技股份有限公司投资者关系活动记录表 编号：2026-009 | | □特定对象调研 | | □分析师会议 | | | --- | --- | --- | --- | --- | | 投资者关系 | □媒体采访 | | □业绩说明会 | | | 活动类别 | □新闻发布会 | ☑ | 路演活动 | | | | □现场参观 | | | | | | □其他 | （请文字说明其他活动内容） | | | | | 宝盈基金 | 林艾灵 | 交银基金 | 朱亦宁 | | | 博时基金 | 张涵 | 南方基金 | 张德曦、蔡强 | | | 博衍基金 | 熊文说 | 农银汇理 | 李蕾 | | | 大成基金 | 陈泉龙 | 盘京投资 | 曹姗姗 | | | 淡水泉 | 胡学森 | 鹏华基金 | 李建国 | | | 东吴基金 | 毛可君 | 平安基金 | 刘文平、黄维、黄文敏 | | | 富国基金 | 吕泽楠 | 平安资管 | 刘博 | | | 高毅资产 | 刘慧敏 | 太平资产 | 许希晨 | | | 工银瑞信 | 李乾宁 | 天弘基金 | 齐震 | | 参与单位名称 ...

Q3：请公司介绍下目前新园区的建设进度和产能的情况以及厂房规划？ 证券代码：301580 证券简称：爱迪特 爱迪特（秦皇岛）科技股份有限公司投资者关系活动记录表 编号：2026-008 | ☑ | 特定对象调研 | □分析师会议 | | --- | --- | --- | | 投资者关系 | □媒体采访 | □业绩说明会 | | 活动类别 | □新闻发布会 | □路演活动 | | ☑ | 现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称 及人员姓名 | 国投证券 贾宏坤、孙琳越 | | | | 中信证券 郭柯宇 | | | | 西部证券 陆伏崴 | | | | 华鑫证券 胡博新 | | | | 深圳众诚创想投资 李旦 | | | 时间 | 2026 年 3 月 17 日 | | | 地点 | 公司会议室 | | | 上市公司接待 人员姓名 | 董事会秘书 郜雨 | | | 投资者关系活动主 | Q1: 请公司介绍下公司的营销模式以及海外收入占比的情况？ | | | | 公司采用境内外差异化的营销模式，核心以直销为基础，海外配套 | | | | 经销模式，且报价、折扣及合作 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of products with price leadership amid rising costs in the supply chain due to geopolitical tensions and policy changes affecting raw material prices [2] - The report highlights the significant price increases in pharmaceutical raw materials, particularly vitamins and amino acids, which have seen price increases of 40.54% and 84.66% respectively since the beginning of the year [2] - The report notes the approval of China's first invasive brain-machine interface, marking a significant milestone in the medical device sector [5] - The report indicates a strong trend in China's innovative pharmaceuticals going global, with a notable increase in licensing-out transactions [6] Summary by Sections 1. Supply Chain Dynamics - The report discusses the impact of rising prices in upstream chemical products on pharmaceutical raw materials, stressing that the ability to pass on these costs is crucial for maintaining profitability [2] - It mentions that 90% of monitored products have seen price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] 2. Market Trends in Disposable Gloves - The report details the price increases in disposable nitrile gloves and PVC gloves due to rising costs of raw materials like butadiene and acrylonitrile, which have increased by 84.43% and 47.30% respectively [3] - It notes that the domestic utilization rate for nitrile gloves has improved, and export prices have been rising since late 2025 [3] 3. Regulatory Environment - The report highlights the impact of dual-use item management on the pricing of key materials, creating significant price disparities between domestic and international markets [4] - It suggests that stricter controls on resources like rare earths could enhance the competitive advantage of domestic medical products [4] 4. Innovations in Medical Devices - The report discusses the approval of the brain-machine interface by the National Medical Products Administration, which is expected to open new market opportunities [5] - It outlines the potential for significant market growth in this area, given the high number of spinal cord injury patients in China [5] 5. International Expansion of Chinese Pharmaceuticals - The report notes that there have been 39 licensing-out transactions in the innovative drug sector, with upfront payments totaling approximately $2.953 billion [6] - It emphasizes that the trend of Chinese pharmaceuticals going global continues to strengthen, with a focus on small nucleic acid drugs and dual antibodies [7] 6. Stock Recommendations - The report recommends focusing on raw material suppliers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Inco Medical and Blue Sail Medical in the disposable glove sector [8] - It also suggests monitoring companies involved in the invasive brain-machine interface and small nucleic acid drugs, indicating potential for growth in these areas [8]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of price leadership in the pharmaceutical sector, particularly in the context of rising raw material costs due to geopolitical tensions and supply chain disruptions [2] - The report highlights the approval of China's first invasive brain-machine interface, marking a significant milestone in medical technology and potential market opportunities [5] - The report notes a strong trend in China's innovative drug exports, with a significant increase in licensing deals and collaborations, indicating robust growth in the sector [6] Summary by Sections Supply Chain and Pricing Dynamics - The report discusses the impact of macroeconomic changes on supply chains, particularly the price increases in upstream chemical products affecting pharmaceutical raw materials [2] - It mentions that 90% of monitored products saw price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] - Specific raw materials like Vitamin E and methionine have seen price increases of 40.54% and 84.66% respectively since the start of the year [2] Market Trends and Innovations - The report details the rising prices of disposable gloves due to increased costs of upstream materials, with notable price hikes in butadiene and acrylonitrile [3] - It highlights the competitive landscape for disposable gloves, noting that leading companies are leveraging their cost advantages to implement price increases [3] - The report also discusses the potential for domestic medical products to benefit from export controls on dual-use items, enhancing China's competitive edge [4] Regulatory Developments and Market Opportunities - The approval of the brain-machine interface by the National Medical Products Administration is a significant development, with a large potential patient base in China [5] - The report outlines the introduction of new pricing guidelines for invasive brain-machine interfaces, which could facilitate market entry and reimbursement [5] Investment Recommendations - The report recommends focusing on raw material producers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Yingke Medical and Blue Sail Medical in the disposable glove sector [8] - It suggests monitoring companies benefiting from resource management policies, such as Aidi Te, and those involved in the invasive brain-machine interface market, like Meihua Medical [8] - The report also emphasizes the growth potential in the small nucleic acid drug sector, recommending companies like Yuyuan Pharmaceutical and Sunshine Nuohe [8] Company Performance and Forecasts - The report provides earnings forecasts for key companies, indicating a positive outlook for several firms in the pharmaceutical sector, with specific EPS and PE ratios highlighted for investment consideration [9]

公司设备板块聚焦口腔数字化设备，涵盖口内扫描仪、3D 打印机 等品类，是公司第二大业务板块，目前国内+海外市场双布局，增速逐 步回升，成为公司重要的增长点。口腔数字化设备渗透率持续提升，市 场规模与材料板块近乎持平，公司计划推动设备与材料收入实现 1:1 的 目标，发展空间广阔。 Q4：请问公司参股景德镇万微粉体的发展情况和扩产计划？ 公司为景德镇万微粉体的战略股东，持股 42%，是核心原材料的重 要供应方，双方形成深度的产业协同关系，万微新材当前发展态势良好， 且已明确落地扩产计划，将进一步提升其氧化锆粉体制备能力，不仅能 持续为公司提供稳定的原材料供应，还能支撑其自身多领域业务的增速 需求，对标海外高端粉体。 Q5：请问公司 3D 打印业务的发展情况以及新厂房扩建的影响？ 证券代码：301580 证券简称：爱迪特 爱迪特（秦皇岛）科技股份有限公司投资者关系活动记录表 编号：2026-007 投资者关系 活动类别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 及人员姓名 平安基金 宁特林 时间 2026 年 ...

证券代码：301580 证券简称：爱迪特 公告编号：2026-005 爱迪特（秦皇岛）科技股份有限公司 关于合计持股 5%以上股东权益变动触及 1%刻度的公告 合计持股 5%以上股东苏州君联欣康创业投资合伙企业（有限合伙）和 HEALTH ADVANCE LIMITED 保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）于 2026 年 1 月 15 日在巨潮资讯网披露了《关于持股 5%以上股东减持股份预披露公告》（公告 编号：2026-001）（以下简称"本次减持计划"）。公司持股 5%以上股东苏州 君联欣康创业投资合伙企业（有限合伙）（以下简称"君联欣康"）以及康拓有 限公司（HEALTH ADVANCE LIMITED）（以下简称"HAL"）计划自上述公 告披露之日起 15 个交易日之后 3 个月内通过集中竞价或大宗交易方式减持公司 股份，减持数量合计不超过 3,196,930 股（占公司总股本的 3.0000%）。其中， 通过集中竞价方式 ...

2026 年 02 月 28 日 投资央山医疗，加速产业协同 买入(首次) 事件 | | | | 基本数据 | 2026-02-27 | | --- | --- | | 当前股价（元） | 87 | | 总市值（亿元） | 93 | | 总股本（百万股） | 107 | | 流通股本（百万股） | 72 | | 52 周价格范围（元） | 36.96-87 | | 日均成交额（百万元） | 98.48 | 市场表现 资料来源：Wind，华鑫证券研究 -40 -20 0 20 40 60 80 100 120 (%) 爱迪特 沪深300 相关研究 —爱迪特（301580.SZ）公司事件点评报告 爱迪特于 2026 年 2 月 27 日官宣以产业战略投资人身份完成 对上海央山医疗科技有限公司（以下简称"央山医疗"） Pre-A+轮战略投资。 爱迪特于 2026 年 1 月 30 日发布新品 3DPro zir Ultra。 投资要点 ▌战略投资央山医疗，完善数字化齿科生态布局 公司战略投资央山医疗，有助于在口腔种植领域构建"材料+ 设备+服务"一体化的数字化诊疗生态。公司主营业务为氧化 锆瓷块等口腔修复材料，并于 ...

2026 年 02 月 28 日 投资央山医疗，加速产业协同 买入(首次) 事件 | | | | 基本数据 | 2026-02-27 | | --- | --- | | 当前股价（元） | 87 | | 总市值（亿元） | 93 | | 总股本（百万股） | 107 | | 流通股本（百万股） | 72 | | 52 周价格范围（元） | 36.96-87 | | 日均成交额（百万元） | 98.48 | 市场表现 资料来源：Wind，华鑫证券研究 -40 -20 0 20 40 60 80 100 120 (%) 爱迪特 沪深300 相关研究 —爱迪特（301580.SZ）公司事件点评报告 爱迪特于 2026 年 2 月 27 日官宣以产业战略投资人身份完成 对上海央山医疗科技有限公司（以下简称"央山医疗"） Pre-A+轮战略投资。 爱迪特于 2026 年 1 月 30 日发布新品 3DPro zir Ultra。 投资要点 ▌战略投资央山医疗，完善数字化齿科生态布局 公司战略投资央山医疗，有助于在口腔种植领域构建"材料+ 设备+服务"一体化的数字化诊疗生态。公司主营业务为氧化 锆瓷块等口腔修复材料，并于 ...

Core Viewpoint - The strategic investment by Aidi Te in Shanghai Yangshan Medical Technology aims to enhance the digital dental ecosystem by integrating Aidi Te's industrial capital and channel resources with Yangshan Medical's R&D capabilities in dental hard technology [1][2]. Group 1: Investment Details - Aidi Te completed a Pre-A+ round strategic investment in Yangshan Medical, focusing on a comprehensive ecosystem of "materials + equipment + services" [1]. - Aidi Te has nearly 20 years of experience in the dental field, providing support in market channels and industrial implementation for Yangshan Medical [1]. - Aidi Te's core products include zirconia blocks and glass ceramics, with nearly 70% of its revenue coming from international markets [1]. Group 2: Yangshan Medical's Focus - Yangshan Medical specializes in dental hard technology, particularly in robotics, artificial intelligence, and innovative medical devices for oral and maxillofacial surgery [2]. - The core team of Yangshan Medical has an international background, with expertise in robotics, oral medicine, and artificial intelligence [2]. - Yangshan Medical's recent achievement includes the approval of China's first contact navigation technology-based dental implant surgery robot, PlanT, which fills a gap in the domestic market [3]. Group 3: Strategic Synergies - The investment aligns with the industry's shift from price competition to technology differentiation, addressing the demand for precision and efficiency in clinical implants [2][3]. - Aidi Te's global marketing network will support the promotion and market penetration of Yangshan Medical's products [4]. - The collaboration aims to transform from a single supplier of dental consumables and equipment to a provider of integrated digital dental treatment solutions [4].